Optimization of a polysaccharide-based nanocarrier for targeted ocular drug delivery of antiglaucoma agents.

Project Abstract

The present study reports the design, synthesis, and evaluation of a polysaccharide-based nanocarrier system engineered for targeted delivery of antiglaucoma agents to ocular tissues, aiming to enhance therapeutic efficacy while minimizing systemic exposure and dosing frequency. A biocompatible polysaccharide backbone (e.g., chitosan or hyaluronic acid derivatives) was functionalized with targeting ligands and mucoadhesive moieties to facilitate rapid pre-corneal residence time and selective uptake by retinal pigment epithelial and ciliary body cells. Nanocarriers were fabricated using ionic gelation and/or nanoprecipitation to achieve a size distribution around 100–200 nm, surface charge in the range of +15 to +25 mV, and high drug loading efficiency for representative antiglaucoma agents such as betaxolol, timolol, and brimonidine. The system integrates pH-responsive and enzyme-responsive linkages to enable controlled drug release in the intraocular environment, thereby maintaining therapeutic concentrations within target tissues while reducing peak-related toxicity. In vitro characterization included dynamic light scattering, zeta potential, transmission electron microscopy, differential scanning calorimetry, and Fourier-transform infrared spectroscopy to confirm nanoparticle integrity and drug–polymer interactions. Mucoadhesion assays and ex vivo corneal permeation studies using bovine and porcine models quantified retention and permeation profiles, while cytotoxicity was evaluated on human corneal epithelial and retinal cell lines to establish biocompatibility. In vivo pharmacokinetic and biodistribution studies in relevant animal models demonstrated prolonged ocular residence time, enhanced transcorneal penetration, and preferential distribution to trabecular meshwork and conjunctival tissues, with markedly reduced aqueous humor turnover and systemic bioavailability compared with conventional ophthalmic formulations. Efficacy assessments included measurement of intraocular pressure reduction, duration of action, and protective effects against oxidative stress–induced damage in retinal cells, alongside histopathological evaluation to detect potential tissue inflammation or toxicity. The imaging-guided assessment utilized noninvasive modalities such as fluorescence and confocal microscopy to monitor localization and clearance kinetics of labeled nanocarriers. Data analysis employed multivariate optimization to correlate physicochemical properties with biological outcomes, enabling fine-tuning of polymer composition, ligand density, and crosslinking degree to maximize targeting efficiency and minimize off-target effects. The results indicate that the optimized polysaccharide-based nanocarrier achieves improved bioavailability, sustained drug release, and superior intraocular pressure control compared with standard eye drops, while maintaining a favorable safety profile. Sensitivity analyses confirmed robustness against formulation variability, and scalability assessments suggested feasible translation to clinical-grade manufacturing. This work provides a versatile platform for ocular drug delivery that can be adapted to a wide range of antiglaucoma agents and potentially extended to other anterior and posterior segment diseases, addressing a critical need for effective, patient-friendly glaucoma management.

Project Overview

What This Project Is About

---

A straightforward, beginner-friendly look at using tiny sugar-based carriers to deliver eye medicines more precisely to the front part of the eye. The project explores how these carriers can improve how well antiglaucoma drugs work and reduce side effects.

---

---

The Problem It Addresses

---

Many glaucoma drugs don’t stay long enough on the eye or reach the right spots, so patients need frequent dosing. This can cause adherence problems and more side effects. The project aims to design a biocompatible carrier that can hold a drug and release it where it’s needed.

---

---

Objectives of the Project

---

1. Understand how polysaccharide carriers can be used for eye drug delivery.
2. Prepare a simple nanocarrier that can carry an antiglaucoma drug.
3. Characterize the carrier’s size, stability, and drug load.
4. Test how the carrier releases the drug over time under eye-like conditions.
5. Evaluate safety on eye-like tissues in vitro.

---

---

What You Will Do Step by Step

---

1) Review basic literature on eye anatomy and drug delivery systems. 2) Choose a polysaccharide and prepare the nanocarrier. 3) Load the drug and measure how much is carried. 4) Study release in a simulated tear environment. 5) Assess stability and particle size. 6) Perform basic compatibility and safety checks using simple cell models. 7) Analyze data to see release patterns and correlations. 8) Discuss practical implications and potential improvements.

---

---

Expected Outcome

Clear understanding of whether the polysaccharide carrier can improve drug delivery to the eye, with data on stability, release timing, and safety. The project should provide a proof-of-concept for a safer, more effective glaucoma treatment option.